Roche to Invest USD 50 Billion in United States for Pharmaceuticals and Diagnostics Over the Next Five Years

More than 12,000 new jobs will be created by investments, including 1,000 at Roche and more than 11,000 to support the development of new manufacturing capabilities in the US.

In the next five years, Roche plans to invest USD 50 billion in the United States of America. With 13 manufacturing and 15 research and development locations spread across the Pharmaceutical and Diagnostics Divisions, Roche’s already sizable US footprint is further strengthened by these investments, which are anticipated to generate over 12,000 new jobs, including almost 6,500 construction jobs and 1,000 jobs at new and expanded facilities. Roche will expand its current workforce of over 25,000 workers in 24 locations in eight US states as part of this investment.

Advertisement

The investment mainly includes:

  1. Enhanced US production and distribution capacities for its cutting-edge drug and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California.
  2. A brand-new 900,000 square foot production facility to support Roche’s growing line of cutting-edge weight-loss medications.
  3. A cutting-edge gene therapy production plant in Pennsylvania

Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US,

We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.

Thomas Schinecker

Roche will export more medications from the US than it imports once all of its new and expanded production capacity is operational. Its diagnostics branch already exports excess to other nations from the United States.

Also Read:  European Commission Approves Roche's Columvi® (glofitamab) For B-cell Lymphoma Based on the Phase III STARGLO Study Results
Advertisement

Source: Roche

Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.

Ajmal Aseem

Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.

Next Post

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for TrenibotulinumtoxinE (TrenibotE), Treating Glabellar Lines

Thu Apr 24 , 2025
Written by Ajmal Aseem | Reviewed by Editor's Desk AbbVie declared that they had submitted the Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE) to the United States FDA for the treatment of moderate to severe glabellar lines. The submission provides evidence of TrenibotE’s differentiated clinical profile to offer patients an opportunity to experience a faster […]
AbbVie

Related Articles